Risk Factors of Coronary In–Stent Restenosis in Drug-Eluting Stent: A Systematic Review and Meta-Analysis
Keywords:
Drug-eluting stents, Meta-analysis, Risk factor ISR, Systematic reviewAbstract
Background: In-stent restenosis (ISR) is an event of coronary atherosclerosis re-budling following the stent implantation in percutaneous coronary intervention. The events of ISR have been significantly reduced since the introduction of drug-eluting stents. However, ISR could still occur, and factors affecting the incident have not yet been discovered. This study aims to evaluate the risk factors of coronary in-stent restenosis in drug-eluting stents. Methods: Studies on the factors and risks of ISR in patients with drug-eluting stents were systematically searched in databases (PubMed, ScienceDirect, Springer, Google Scholar, and ProQuest) on September 20th, 2023. The odds ratio (OR) and mean difference (MD) were analyzed using Review Manager 5.4. Results: Diabetes mellitus (OR 1.73 [95%CI 1.56, 1.91] p < 0.00001) and smoking (OR 1.24 [95%CI 1.13, 1.36] p<0.0001) are the patients' clinical characteristics that are associated with ISR in DES. It is closely related to the contribution of diabetes mellitus in promoting platelet adhesion and smoking in enhancing intimal hyperplasia. As in the angiography characteristics, stent lesion at LAD (OR 1.20 [95%CI 1.07, 1.35] p = 0.002) and stent length (MD 3.61 [95%CI 1.81, 5.42] p < 0.0001) are correlated with the events of ISR. Every millimeter excess of stent length significantly increases the risk of ISR. Therefore, reducing the excess stent length may contribute to the reduced risk of ISR in DES. Conclusion: The identification of risk factors contributing to ISR in DES may help cardiologists modify the attributable factors and prevent the occurrence of ISR.References
D.-M. Alexandrescu, et al. Risk factors associated with intra stent restenosis after percutaneous coronary intervention. Exp. Ther. Med.. 2021;22(4)1–7. doi: 10.3892/etm.2021.10575.
Ochijewicz D, Tomaniak M, Opolski G, Kochman J. Inflammation as a determinant of healing response after coronary stent implantation. Int. J. Cardiovasc. Imaging. 2021;37(3):791–801 [Online]. Available: https://doi.org/10.1007/s10554-020-02073-3
Stolker JM, et al. Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. Circ. Cardiovasc. Interv. 2012;5(6):772–82 [Online]. Available: https://doi.org/10.1161/CIRCINTERVENTIONS.111.967802
Canbolat IP, Arat-özkan A. Predictors of in-stent restenosis in patients undergoing percutaneous coronary intervention Perkütan koroner girişim geçiren hastalarda stent-içi restenozun öngörücüleri. J. Med. 2019;5(2):87–90. doi: 10.5606/fng.btd.2019.015.
Cheng G, et al. Factors influencing stent restenosis after percutaneous coronary intervention in patients with coronary heart disease: A clinical trial based on 1-year follow-up. Med. Sci. Monit. 2019;25:240–7. doi: 10.12659/MSM.908692.
Feng Q, Zhao Y, Wang H, Zhao J, Wang X, Shi J. A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients. Front. Cardiovasc. Med. 2022;9(August):1–10. doi: 10.3389/fcvm.2022.857922.
Jiang Z, et al. Random forest vs. Logistic regression: predicting angiographic in - stent restenosis sfter second - generation drug - eluting stent implantation. PLoS One. 2022;17(5):1–13. doi: 10.1371/journal.pone.0268757.
Jing XD, Wei XM, Deng SB, Du JL, Liu YJ, She Q. The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis. Clin. Chim. Acta. 2015;446:248–52. doi: 10.1016/j.cca.2015.04.038.
M. Li, J. Hou, X. Gu, R. Weng, Z. Zhong, S. Liu, Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China. Eur. J. Med. Res. 2022;27(1):1–7. doi: 10.1186/s40001-022-00640-z.
Y. Luo, et al. Prognostic role of fasting remnant cholesterol with in-stent restenosis after drug-eluting stent implantation. Int. J. Gen. Med. 2022;15(Feb):1733–42. doi: 10.2147/IJGM.S348148.
D. Nakamura, et al. Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis. Euro Intervention. 2021;17(6):489–96. doi: 10.4244/EIJ-D-20-00539.
Z. Qin, et al. Elevated levels of very low-density lipoprotein cholesterol independently associated with in-stent restenosis in diabetic patients after drug-eluting stent implantation. Chin. Med. J. (Engl). 2017;130(19): 2326–32. doi: 10.4103/0366-6999.213575.
Song T, et al. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI. BMC Cardiovasc. Disord. 2021;21(1)1–10. doi: 10.1186/s12872-020-01839-w.
Tocci G, et al. Blood pressure levels at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosis. Am. J. Hypertens. 2016;29(4):509–18. doi: 10.1093/ajh/hpv131.
Wang P, Qiao H, Wang RJ, Hou R, Guo J. The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do. BMC Cardiovasc. Disord. 2020;20(1):1–6. doi: 10.1186/s12872-020-01798-2.
Xi H, et al. Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease. Front. Cardiovasc. Med. 2023;10(March)1–11. doi: 10.3389/fcvm.2023.1117915.
Zhao J, Wang X, Wang H, Zhao Y, Fu X. Occurrence and predictive factors of restenosis in coronary heart disease patients underwent sirolimus-eluting stent implantation. Ir. J. Med. Sci. 2020;189(3):907–15. doi: 10.1007/s11845-020-02176-9.
Zhao SG. CHA2DS2-Vasc score and CHA2DS2-Vasc-HS score are poor predictors of in-stent restenosis among patients with coronary drug-eluting stents. J. Int. Med. Res. 2019;47(6):2533–44. doi: 10.1177/0300060519841836.
Zhao K, Li YJ, Gao S. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting. Coron. Artery Dis. 2015;26(3):220–4. doi: 10.1097/MCA.0000000000000221.
Wu Y, Fu X. Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation. J. Clin. Lab. Anal. 2019;33(2):1–13. doi: 10.1002/jcla.22666.
Wang JL, et al. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. J. Geriatr. Cardiol. 2018;15(2):137–45 [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895953/
Zhou J, Chai D, Dai Y, Wang A, Yan T, Lu S. Predictive value analysis of in-stent restenosis within three years in older acute coronary syndrome patients: a two-center retrospective study. Clin. Appl. Thromb. 2022;289(58):1–9. doi: 10.1177/10760296221107888.
Zhu Y, et al. Atherogenic index of plasma and the risk of in-stent restenosis in patients with acute coronary syndrome beyond the traditional risk factors. J. Atheroscler. Thromb. 2022;29(8):1226–35. doi: 10.5551/jat.63136.
Zhang L, et al. Risk factors of in-stent restenosis among coronary artery disease patients with syphilis undergoing percutaneous coronary intervention: a retrospective study. BMC Cardiovasc. Disord. 2021;21(1):1–11. doi: 10.1186/s12872-021-02245-6.
Zeng MY, Yan XW, Wu W. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis. BMC Cardiovasc. Disord. 2021;21(1):1–9. doi: 10.1186/s12872-021-02259-0.
Chen BW, et al. Analysis of the correlation between the ratio of monocytes to high-density lipoprotein cholesterol and in-stent restenosis in patients with premature coronary heart disease. Clin. Appl. Thromb. 2022;28:1–9. doi: 10.1177/10760296221079334.
Gabbasov Z, et al. Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease. Wien. Klin. Wochenschr. 2016;(128):23–4, 898–905. doi: 10.1007/s00508-016-1074-x.
Nan J, et al. The predictive value of monocyte count to high-density lipoprotein cholesterol ratio in restenosis after drug-eluting stent implantation. Int. J. Gen. Med. 2020;13:1255–63. doi: 10.2147/IJGM.S275202.
Qian H, et al. Red cell distribution width in coronary heart disease: prediction of restenosis and its relationship with inflammatory markers and lipids. Postgrad. Med. J. 2018;94(1115):489–94. doi: 10.1136/postgradmedj-2018-135806.
Tanindi A, Ekici B, Töre HF. Do pre-procedural laboratory parameters predict drug-eluting stent restenosis? Turk Kardiyol. Dern. Ars. 2015;43(5): 457–64. doi: 10.5543/tkda.2015.48275.
Li C, et al. Evaluation of preprocedural laboratory parameters as predictors of drug-eluting stent restenosis in coronary chronic total occlusion lesions. Angiology. 2019;70(3):272–8. doi: 10.1177/0003319717752245.
Holmberg J, et al. Loss of vascular myogenic tone in mir-143/145 knockout mice is associated with hypertension-induced vascular lesions in small mesenteric arteries. Arterioscler. Thromb. Vasc. Biol., 2018;38(2):414–24 [Online]. Available: https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.117.310499
Geraldes R, et al. Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2020;91(4):388–91 [Online]. Available: https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.117.310499
Maor GS, Faden MS, Brown R. Prevalence, risk factors and pregnancy outcomes of women with vascular brain lesions in pregnancy. Arch. Gynecol. Obstet. 2020;301(3):665–70 [Online]. Available: https://doi.org/10.1007/s00404-020-05451-3
Ferraro RA, et al. Non-obstructive high-risk plaques increase the risk of future culprit lesions comparable to obstructive plaques without high-risk features: The ICONIC study. Eur. Heart J. Cardiovasc. Imaging, 2020;21(9):973–80 [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/32535636/
Song B, Kim D, Nguyen NH, Roy S. Inhibition of diabetes-induced lysyl oxidase overexpression prevents retinal vascular lesions associated with diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2018;59(15):5965–72 [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295938/
Huang X, et al. Impact of cigarette smoking and smoking cessation on stent changes as determined by optical coherence tomography after sirolimus stent implantation. Am. J. Cardiol. 2017;120(8): 1279–84, 2017 [Online]. Available: https://doi.org/10.1016/j.amjcard.2017.07.011
Villablanca AC. Nicotine stimulates DNA synthesis and proliferation in vascular endothelial cells in vitro. J. Appl. Physiol. 1998;84(6):2089–8 [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/9609804/
Hamasaki, et al. Effect of nicotine on the intimal hyperplasia after endothelial removal of the rabbit carotid artery. Gen. Pharmacol. 1997;28(5):653–9 [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/9184797/
Mehta A, et al. Lipoprotein(a) and family history predict cardiovascular disease risk. J. Am. Coll. Cardiol. 2020;76(7):781–93 [Online]. Available: https://doi.org/10.1016/j.jacc.2020.06.040
Moreno R, et al. Long-term outcome of patients with proximal left anterior descending coronary artery in-stent restenosis treated with a second percutaneous procedure. J. Invasive Cardiol. 2005;17(4):218–21 [Online]. Available: https://onlinelibrary.wiley.com/doi/full/10.1002/ccd.1098
Guardado JH, et al. Proximal left anterior descending coronary artery revascularization with drug-eluting stents. Arq. Bras. Cardiol. 2007;88(2):137–43 [Online]. Available: https://doi.org/10.1590/S0066-782X2007000200005
Rodriguez A, et al. Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal lad stenosis: Results from the ERACI II study. Heart. 2003;89(2):184–8 [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767529/
Henderson R. A, et al. Long-term results of RITA-1 trial: Clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Lancet. 1998;352(9138):1419–25 [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/9807988/
Design S. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N. Engl. J. Med. 2001;344(15):1117–24 [Online]. Available: https://doi.org/10.1056/nejm200104123441502
Sawhney N, et al. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation. 2004;110(4):374–9 [Online]. Available: https://www.ahajournals.org/doi/10.1161/01.CIR.0000136580.34604.B8
Choi IJ, et al. Impact of the stent length on long-term clinical outcomes following newer-generation drug-eluting stent implantation. Am. J. Cardiol. 2014;113(3):457–64 [Online]. Available: http://dx.doi.org/10.1016/j.amjcard.2013.10.029
Hong MK, et al. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. Eur. Heart J. 2006;27(11):1305–10 [Online]. Available: https://doi.org/10.1093/eurheartj/ehi882
Mauri L, et al. Effects of stent length and lesion length on coronary restenosis. Am. J. Cardiol. 2004;93( 11): 1340–6 [Online]. Available: https://www.ajconline.org/article/S0002-9149(04)00275-9/fulltext
Stone GW, et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the horizons-ami (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J. Am. Coll. Cardiol. 2010;56(19):1597–604 [Online]. Available: https://doi.org/10.1016/j.jacc.2010.08.608
Wang Z, Liu C, Fang H. Blood cell parameters and predicting coronary in-stent restenosis. Angiology. 2019;70(8)711–8 [Online]. Available: https://doi.org/10.1177/0003319719830495
Choi YH, Hong YJ, Ahn Y, Park IH, Jeong MH. Relationship between neutrophil-to-lymphocyte ratio and plaque components in patients with coronary artery disease: virtual histology intravascular ultrasound analysis. J. Korean Med. Sci. 2014;29(7):950–6 [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/26535014/
Chang Z, Zheng J, Liu Z, Guo Q. The relationship between the neutrophil-lymphocyte ratio and in-stent restenosis in patients with femoropopliteal chronic total occlusions. Angiology. 2018;69(2):177–82 [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/28635304/
Turak O, et al. Usefulness of the neutrophil to lymphocyte ratio to predict bare metal stent restenosis.Am. J. Cardiol. 2012;110(10):1405–10 [Online]. Available: http://dx.doi.org/10.1016/j.amjcard.2012.07.003
Demirkol S, et al. Assessment of the relationship between red cell distribution width and cardiac syndrome X. Kardiol. Pol. 2013;71(5):480–4 [Online]. Available: https://journals.viamedica.pl/kardiologia_polska/article/view/77451
Weiss G, Goodnough LT. Anemia of chronic disease. N. Engl. J. Med. 2019;352(10):1011–23 [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/15758012/
Yildiz A, Tekiner F, Karakurt A, Sirin G, Duman D. Preprocedural red blood cell distribution width predicts bare metal stent restenosis. Coron. Artery Dis. 2014;25(6):469–73 [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/15758012/
Okada T, Yuge M, Kawaguchi T, Hojo Y. The urinary albumin-to-creatinine ratio is a potential predictor of target lesion revascularization after percutaneous coronary intervention with coronary stents. Int. Heart J. 2014;55(5):409–15 [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/25088583/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Hotmauli Siahaan, Paulus Parholong Siahaan, Pandit Bagus Tri Saputra, Jannatin Nisa Arnindita, Rizky Novita Anjaswanti, David Setyo Budi, Yudi Her Oktaviono, Hari Basuki Notobroto
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
